Table 2.
Quantitative PCR determination of the RNA steady state level in HTB161 and HTB75 cell lines of RAD51 gene, after treatment with F7 and/or niraparib for 6 and 9 h relative to control.
| RAD51 Expression in HTB161 (Mean ± SE) | RAD51 Expression in HTB75 (Mean ± SE) | |||
|---|---|---|---|---|
| Duration of Treatment | 6 h | 9 h | 6 h | 9 h |
| Control | 1.00 ± 0.04 A | 1.00 ± 0.00 a | 1.00 ± 0.10 A | 1.01 ± 0.12 a |
| F7 | 0.54 ± 0.01 B | 0.73 ± 0.05 b | 0.67 ± 0.04 A | 0.89 ± 0.05 a |
| Niraparib | 0.63 ± 0.02 B | 0.59 ± 0.02 bc | 1.30 ± 0.24 A | 1.02 ± 0.16 a |
| Niraparib+F7 | 0.65 ± 0.08 B | 0.55 ± 0.03 c | 0.83 ± 0.09 A | 1.15 ± 0.04 a |
Control was the vehicle control (1% v/v methanol + 0.6% v/v DMSO). Concentrations used: for HTB75, niraparib 6 µg/mL, F7 17.5 µg/mL; for HTB161, niraparib 25 µg/mL, F7 20 µg/mL. Gene transcript values were determined by quantitative PCR as a difference between the target gene versus a reference gene (HPRT). Values were calculated relative to the average expression of target genes in the treated versus control using the 2−ΔΔCt method. Levels with different Upper or lower case letters with the same font and style were significantly different from all combinations of pairs by Tukey-Kramer honest significant difference (HSD; p ≤ 0.05; n = 3).